BioAtla/BCAB

$2.24

2.75%
-
1D1W1MYTD1YMAX

About BioAtla

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Ticker

BCAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jay Short

Employees

65

Headquarters

San diego, United States

BioAtla Metrics

BasicAdvanced
$101.24M
Market cap
-
P/E ratio
-$2.58
EPS
1.27
Beta
-
Dividend rate
$101.24M
1.26751
$4.07
$1.24
530.54K
4.107
-71.49%
-98.37%
-84.01%
1.432
1.433
5.71%

What the Analysts think about BioAtla

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
413.39% upside
High $14.00
Low $7.00
$2.24
Current price
$11.50
Average price target

BioAtla Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-26.9M
-19.22%
Profit margin
0%
-

BioAtla Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.5%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.58
-$0.75
-$0.70
-
-
Expected
-$0.63
-$0.64
-$0.80
-$0.79
-$0.54
Surprise
-7.64%
17.19%
-12.5%
-
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for BioAtla stock?

BioAtla (BCAB) has a market cap of $101.24M as of April 24, 2024.

What is the P/E ratio for BioAtla stock?

The price to earnings (P/E) ratio for BioAtla (BCAB) stock is 0 as of April 24, 2024.

Does BioAtla stock pay dividends?

No, BioAtla (BCAB) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next BioAtla dividend payment date?

BioAtla (BCAB) stock does not pay dividends to its shareholders.

What is the beta indicator for BioAtla?

BioAtla (BCAB) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the BioAtla stock price target?

The target price for BioAtla (BCAB) stock is $11.5, which is 413.39% above the current price of $2.24. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell BioAtla stock

Buy or sell BioAtla stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing